EX-99.1 3 d57860_ex99-1.txt EARNINGS RELEASE Exhibit 99.1 Company Contacts: Investor Relations Contacts: E-Z-EM, Inc. Lippert/Heilshorn & Associates, Inc. ------------ ------------------------------------ Dennis J. Curtin, CFO x3320 Kim Sutton Golodetz (kgolodetz@lhai.com) Tom Johnson, x3317 ------------------ (800) 544-4624 (212) 838-3777 www.ezem.com Bruce Voss (bvoss@lhai.com) ------------ -------------- (310) 691-7100 www.lhai.com ------------ E-Z-EM REPORTS RECORD SECOND QUARTER NET SALES ---------------------------------------------- Conference call to begin at 11:00 a.m. EST Friday, January 9 ------------------------------------------------------------ LAKE SUCCESS, N.Y. (January 8, 2003) - E-Z-EM, Inc. (Amex: EZM) today announced financial results for the three- and six-month periods ended November 29, 2003. Financial highlights of the fiscal second quarter 2004 include the following: o Net sales up 12% to a record $36.9 million; o Net earnings up 79% to $1.8 million; o Earnings per diluted share up 89% to $0.17. Other highlights for the second quarter and recent weeks include: o The U.S. launch by the Company's AngioDynamics subsidiary of the AquaLiner(TM) hydrophilic Ni-Ti alloy guidewire; o Announcement by E-Z-EM, Inc. of a study supporting adoption of virtual colonoscopy as a screening modality for colon cancer presented at the 89th Annual Scientific Assembly of the Radiological Society of North America and published in the New England Journal of Medicine. For the fiscal 2004 second quarter ending November 29, 2003, net sales rose 12% to $36.9 million, compared with $32.9 million in the fiscal 2003 second quarter. These results reflect continued growth in the Company's AngioDynamics subsidiary in the peripheral vascular and other non-coronary diseases sector and strong sales of diagnostic products for the computed tomography (CT) market. Net earnings for the second quarter rose 79% to $1.8 million, compared with $988,000 in the prior-year quarter, and diluted EPS rose 89% to $0.17, compared with $0.09 in the second quarter of fiscal 2003. Fiscal 2004 second quarter net earnings include gains on the sales of securities of $336,000, or $0.03 per diluted share. Gross profit increased 27% to $6.1 million, compared with $4.8 million last year, for a $1.3 million improvement. As a percentage of net sales, gross profit decreased to 51.4% from 54.7% in the year-ago quarter, which was favorably impacted by an inventory valuation adjustment. The current quarter was impacted by sales price erosion and an increased provision for inventory reserves. Fiscal 2004 second quarter operating expenses were $14.2 million, up 5% from $13.6 in the prior-year quarter. Current quarter results include an expense of $628,000 ($0.05 per share) related to the previously announced plan to close later this year the Company's device manufacturing facility in Puerto Rico and its heat-sealing operation in Westbury, N.Y. In the prior-year quarter, the Company 5 recorded an expense of $106,000 ($0.01 per share) associated with the recapitalization of its common stock. Operating profit rose 55% to $2.3 million in the second quarter of fiscal 2004, compared with $1.5 million in the second quarter of fiscal 2003. Other income in the current quarter was $449,000, which includes the gains on sales of securities noted above, compared with other income of $97,000 in the prior-year quarter. Commenting on the quarterly results, Anthony A. Lombardo, E-Z-EM president and chief executive officer, said, "We had an excellent quarter with increased sales in each of our two radiology business segments representing a continuation of trends in peripheral vascular and other non-coronary disease therapeutic applications and in CT imaging, all of which are driving overall market growth. Our AngioDynamics subsidiary performed solidly during the quarter, with sales up 35% over the comparable prior-year quarter." "We continue to make progress in transferring our device manufacturing and heat-sealing operations to a third-party manufacturer. The plan is on time and on budget. As previously announced, we anticipate taking charges of approximately $700,000 related to this initiative in the remaining quarters of this fiscal year, and we expect to begin realizing the related benefits in fiscal year 2005," he added. For the first half of fiscal 2004, net sales increased 11% to a record $70 million, compared with $63.2 million for the first half of fiscal 2003. Net earnings for the first six months of fiscal 2004 were $1.5 million, or $0.14 per diluted share, compared with net earnings of $247,000, or $0.02 per diluted share, for the first six months of fiscal 2003. Operating expenses for the current six-month period were $28.1 million, up 4% from $27.2 million in the comparable prior-year period. The results for the fiscal 2004 six-month period include $1.2 million ($0.10 per share) of expenses related to the previously announced plant closing and operational restructuring. Results for the comparable fiscal 2003 period include $688,000 ($0.07 per share) related to the common stock recapitalization. Operating profit increased sharply to $2.4 million in the first half of fiscal 2004, compared with $390,000 in the comparable fiscal 2003 period. Cash, cash equivalents and short-term marketable securities at November 29, 2003 were $16.0 million, versus $16.4 million at August 30, 2003 and $18.0 million at May 31, 2003. Conference Call E-Z-EM management will host a conference call to discuss these results on Friday, January 9, 2004 at 11:00 a.m. Eastern Standard Time. To participate, dial (877) 815-7177 from the U.S., or (706) 679-0753 from outside the U.S. A telephone replay of the call will be accessible for 48 hours following completion of the call by dialing (800) 642-1687 or (706) 645-9291, and entering reservation number 4734480. 6 About E-Z-EM, Inc. E-Z-EM is the world's largest manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation, the EmpowerCT(R) with patented EDA(TM) technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system. E-Z-EM's wholly owned subsidiary, AngioDynamics, manufactures a wide range of products including angiographic, dialysis, PTA dilation, thrombolytic, image-guided vascular access, endovascular laser venous system, as well as abdominal infection drainage products. AngioDynamics' focus is on therapeutic products that enable interventional physicians to treat peripheral vascular diseases and other non-coronary diseases. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance of virtual colonoscopy as a new imaging procedure, the impact, if any, of the Pickhardt study published in the New England Journal of Medicine, market acceptance of the AquaLiner(TM) hydrophilic Ni-Ti alloy guidewire, the size and quantity of orders for RSDL, successful completion of the Company's Manufacture, Streamlining and Reduction program, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended August 30, 2003, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company. (Tables to follow) 7 E-Z-EM, Inc. and Subsidiaries Consolidated Balance Sheet Highlights (in thousands)
November 29, May 31, 2003 2003 -------- -------- (unaudited) (1) Assets Current Assets Cash, Cash Equivalents and Debt and Equity Securities $ 16,038 $ 17,965 Restricted Cash 220 798 Accounts Receivable, Net 25,370 23,393 Inventories 30,662 28,467 Other Current Assets 4,723 4,703 -------- -------- Total Current Assets 77,013 75,326 Property, Plant & Equipment - at Cost, Net 24,322 23,457 Other Non-Current Assets 13,490 11,841 -------- -------- Total Assets $114,825 $110,624 ======== ======== Liabilities and Stockholders' Equity Current Liabilities $ 16,201 $ 15,203 Long-Term Liabilities 6,844 6,819 Stockholders' Equity 91,780 88,602 -------- -------- Total Liabilities and Stockholders' Equity $114,825 $110,624 ======== ========
(1) Information derived from audited financial statements. 8 E-Z-EM, Inc. and Subsidiaries Consolidated Income Statement Highlights (in thousands, except per share data) (unaudited)
Three Months Ended Six Months Ended ----------------------------- ----------------------------- November 29, November 30, November 29, November 30, 2003 2002 2003 2002 -------- -------- -------- -------- Net Sales E-Z-EM $ 25,287 $ 24,328 $ 47,929 $ 46,511 AngioDynamics 11,851 8,768 22,481 17,096 Eliminations (200) (196) (415) (427) -------- -------- -------- -------- 36,938 32,900 69,995 63,180 Gross Profit (Loss) E-Z-EM 10,475 10,235 18,881 18,568 AngioDynamics 6,092 4,793 11,627 8,961 Eliminations (18) 44 10 40 -------- -------- -------- -------- 16,549 15,072 30,518 27,569 Gross Profit as a Percent of Sales 44.8 45.8 43.6 43.6 Operating Expenses E-Z-EM (1) 9,310 9,564 (2) 18,652 19,572 AngioDynamics 4,905 3,999 9,497 7,607 -------- -------- -------- -------- 14,215 13,563 28,149 27,179 Operating Profit (Loss) E-Z-EM (1) 1,165 671 (2) 229 (1,004) AngioDynamics 1,187 794 2,130 1,354 Eliminations (18) 44 10 40 -------- -------- -------- -------- 2,334 1,509 2,369 390 Other Income (Expense) 449 97 415 414 -------- -------- -------- -------- Earnings Before Income Taxes 2,783 1,606 2,784 804 Income Tax Provision 1,014 618 1,314 557 -------- -------- -------- -------- Net Earnings $ 1,769 $ 988 $ 1,470 $ 247 ======== ======== ======== ======== Earnings per Common Share Basic $ 0.17 $ 0.10 $ 0.14 $ 0.02 Diluted $ 0.17 $ 0.09 $ 0.14 $ 0.02 Weighted Average Common Shares Basic 10,272 10,017 10,217 10,005 Diluted 10,545 10,406 10,475 10,403
(1) Current quarter amount includes plant closing and operational restructuring costs of $628,000; prior quarter amount includes costs associated with the Company's common stock recapitalization of $106,000. (2) Current six-month amount includes plant closing and operational restructuring costs of $1,200,000; prior six-month amount includes costs associated with the Company's common stock recapitalization of $688,000. # # # 9